Health Canada authorizes Moderna COVID-19 vaccine for adults

Health Canada authorizes Moderna COVID-19 vaccine for adults
Share this article

 

OTTAWA – Today, Health Canada authorized the second COVID-19 vaccine in Canada, manufactured by Moderna. Moderna trades on the NASDAQ under the symbol MRNA.

Health Canada says they received Moderna’s submission on October 12, 2020, and after a thorough, independent review of the evidence, has determined that the Moderna vaccine meets the Department’s stringent safety, efficacy and quality requirements.

The different storage and handling requirements of the Moderna COVID-19 vaccine mean that it can be distributed to isolated and remote communities, including the territories.

Health Canada says it is publishing a number of documents related to this decision, including a high-level summary of the evidence that we reviewed to support the authorization of the vaccine. More detailed information will be made available in the coming weeks, including a detailed scientific summary and the full clinical trial data package.

Health Canada and the Public Health Agency of Canada say they will closely monitor the safety of the vaccine once it is on the market and will not hesitate to take action if any safety concerns are identified.

The terms and conditions of the Moderna vaccine authorization require the manufacturer to continue providing information to Health Canada on the safety, efficacy and quality of the vaccine to ensure the benefits of the vaccine continue to be demonstrated through market use.

The vaccine is indicated for use in people 18 years of age or older. Moderna is currently conducting additional studies in children from 12 years of age and older, and this indication could be revised in the future to include children if the data from these studies support it.

The vaccine was authorized under Health Canada’s Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19. This process allowed Health Canada to assess the information submitted by the manufacturer as it became available during the product development process, while maintaining Canada’s high standards.

Moderna’s 52 week low was $17.68 while the 52 week high was $178.50

We seek Safe Harbor.

Related posts

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.